Targets › POLA1
11 programs from 11 companies in 47 trials: 28 Phase 2, 14 Phase 1, 5 Phase 3; Oncology, Neurology, Infectious disease; next expected readout Dec 2026.
Catalytic subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, a regulatory subunit POLA2 and two primase subunits PRIM1 and PRIM2) is recruited to DNA at the replicative forks via direct…. (UniProt, P09884)
Open in Phaseline: the race on POLA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jiangsu Healthy Life Innovation Medical Technology | Gemcitabine hydrochloride Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 3 | Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor … | Dec 2026 |
| Gilead Sciences | Tenofovir Disoproxil Fumarate Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLA1, POLB | Phase 3 | Chronic Hepatitis B; Hepatitis B; Hepatitis B Infection; Parkinson Disease | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | AML | Dec 2026 |
| Dana-Farber Cancer Institute | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Langerhans Cell Histiocytosis | Dec 2026 |
| M.D. Anderson Cancer Center | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Recurrent Acute Lymphoblastic Leukemia | Aug 2027 |
| City of Hope Medical Center | clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Adult Acute Lymphoblastic Leukemia in Remission | Aug 2027 |
| West China Second University Hospital | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Langerhans Cell Histiocytosis (LCH) | Jun 2028 |
| Nantes University Hospital | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 2 | Acute Myeloid Leukemia in Remission | Sep 2028 |
| Princess Maxima Center for Pediatric Oncology | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | Relapsed Pediatric AML | Dec 2026 |
| Ekaterina Laukhtina | Clofarabine Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | Advanced Urothelial Carcinoma | Nov 2028 |
| Beijing Immunochina Medical Science & Technology | Fludarabine Phosphate (IM19) Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor | RRM1, RRM2B, RRM2, POLA1, POLD4 | Phase 1 | NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia … | Jun 2035 |
Acute Myeloid Leukemia in Remission (2) Acute Myeloid Leukaemia (AML) (2) Cancer (2) Metastatic Pancreatic Adenocarcinoma (2) Recurrent Acute Lymphoblastic Leukemia (1) Langerhans Cell Histiocytosis (1) NHL (1) B-cell Acute Lymphoblastic Leukemia (1) Myelodysplastic Syndromes (1) Refractory Idiopathic Aplastic Anemia (1) Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1)
small molecule (7), mixed (2), other (1), protein or peptide (1)
M.D. Anderson Cancer Center (1) Dana-Farber Cancer Institute (1) Nantes University Hospital (1) Beijing Immunochina Medical Science & Technology (1) City of Hope Medical Center (1) Memorial Sloan Kettering Cancer Center (1) Gilead Sciences (1) Jiangsu Healthy Life Innovation Medical Technology (1) Ekaterina Laukhtina (1) West China Second University Hospital (1) Princess Maxima Center for Pediatric Oncology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.